Open access
Vaccines
Observation
7 December 2021

Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve in humans. Spike protein mutations increase transmission and potentially evade antibodies raised against the original sequence used in current vaccines. Our evaluation of serum neutralizing activity in both persons soon after SARS-CoV-2 infection (in April 2020 or earlier) or vaccination without prior infection confirmed that common spike mutations can reduce antibody antiviral activity. However, when the persons with prior infection were subsequently vaccinated, their antibodies attained an apparent biologic ceiling of neutralizing potency against all tested variants, equivalent to the original spike sequence. These findings indicate that additional antigenic exposure further improves antibody efficacy against variants.
IMPORTANCE As SARS-CoV-2 evolves to become better suited for circulating in humans, mutations have occurred in the spike protein it uses for attaching to cells it infects. Protective antibodies from prior infection or vaccination target the spike protein to interfere with its function. These mutations can reduce the efficacy of antibodies generated against the original spike sequence, raising concerns for reinfections and vaccine failures, because current vaccines contain the original sequence. In this study, we tested antibodies from people infected early in the pandemic (before spike variants started circulating) or people who were vaccinated without prior infection. We confirmed that some mutations reduce the ability of antibodies to neutralize the spike protein, whether the antibodies were from past infection or vaccination. Upon retesting the previously infected persons after vaccination, their antibodies gained the same ability to neutralize mutated spike as the original spike, suggesting that the combination of infection and vaccination drove the production of enhanced antibodies to reach a maximal level of potency. Whether this can be accomplished by vaccination alone remains to be determined, but the results suggest that booster vaccinations may help improve efficacy against spike variants through improving not only antibody quantity, but also quality.

OBSERVATION

Evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein results from selection for random mutations that yield fitness benefit that promotes person-to-person dissemination of the virus. Mutations in the receptor-binding domain (RBD), which is involved in viral entry and the key target of neutralizing antibodies, may also facilitate viral resistance to antibodies against the original spike sequence either from prior infection or the current vaccines. Spike variants such as B.1.351/Beta (1) and P.1/Gamma (2) have become predominant over the original sequence of the virus in some geographic locations, and a growing body of evidence suggests that some mutants can contribute to reinfections (3) and vaccine failures (4, 5).
Here, we examine the impact of several commonly observed spike mutations on the serum neutralizing activity of persons who had coronavirus disease 2019 (COVID-19) in April 2020 or earlier, of vaccinated persons who had no prior history of infection, and of the persons who recovered from COVID-19 after subsequent vaccination. This examination directly compares serum neutralization of seven commonly observed spike variant combinations of five RBD mutations by antibodies elicited by vaccination alone, SARS-CoV-2 infection alone, and combined infection and vaccination, to evaluate whether repeated antigenic exposures would increase efficacy of humoral immunity to cope with spike mutations.

Results: mutations in RBD variably reduce the-spike neutralizing activity of antibodies elicited by vaccination.

Serum spike-neutralizing activity was assessed using a spike-pseudotyped neutralization assay and compared to the amount of serum anti-RBD antibodies to yield a measurement of antibody neutralizing potency. In 15 persons without a history of prior infection who were recently vaccinated (7 with BNT162b2 and 8 with mRNA-1273), potency against spike variants was variably less than against the original sequence contained in the vaccine (Fig. 1A). The mutants with the most reduced potency were K417N/E486K/N501Y and K417T/E486K/N501Y found in B.1.351/Beta (1) and P.1/Gamma (2), respectively. In contrast to a prior report (5), K501Y found in B.1.1.7/Alpha exhibited no appreciable resistance to neutralization. There were no clear differences between participants receiving different vaccines, although there were too few subjects for meaningful comparisons. Overall, these results demonstrated that spike mutation can affect the sensitivity to neutralization by antibodies elicited by vaccination with the original spike sequence.
FIG 1
FIG 1 SARS-CoV-2 spike variant neutralizing potency of antibodies generated by vaccination versus natural infection. Potency of serum antibodies against RBD was estimated as the ratio of serum neutralizing activity (log10 dilution factor yielding 80% neutralization of spike-mediated luciferase-expressing lentiviral entry of ACE2-expressing 293T cells) to the concentration of anti-RBD antibodies (log10 nanograms of summed IgG, IgM, and IgA determined by quantitative ELISA using CR3022 monoclonal antibody-based standards) for each of the indicated variants. Potencies were determined against a panel of spike variants containing the indicated mutations. “Original” indicates the unmodified Wuhan-Hu-1 sequence (GenBank accession no. MN908947.3). “Index” is the original sequence with the D614G mutation, and the seven other variants are modifications of the index sequence (containing D614G). (A) Serum antibody neutralizing potencies are shown for 15 persons without prior SARS-CoV-2 infection after recent vaccination 7 to 26 days after completing vaccination (mean, 17 days). Seven received BNT162b2 (red), and eight received mRNA-1273 (blue) vaccines. The P values for comparisons to the original sequence are given above each variant. (B) Serum antibody neutralizing potencies are shown for 10 persons with recent mild SARS-CoV-2 infection (18 to 45 days after onset of symptoms; mean, 31 days). These persons were all infected in the United States prior to May 2020, before substantial prevalence of spike variants appeared. The P values for comparisons to the original sequence are given above each variant. (C) The means and standard errors for potencies against each variant for each group (vaccinees versus recent COVID-19) are plotted against each other.
Mutations in RBD also variably reduce the spike-neutralizing activity of antibodies elicited by natural infection with a similar pattern. Serum antibody spike-neutralizing potency was also assessed for 10 persons with recent mild SARS-CoV-2 infection (mean, 31 days after onset of symptoms; range, 18 to 45 days [see Table S1 in the supplemental material]) who were infected in the United States prior to May 2020, before reports of circulating variants. Again, potency was variably affected by different mutations, and the mutants with most reduced neutralizing potency were K417N/E486K/N501Y and K417T/E486K/N501Y (Fig. 1B). The neutralizing potencies of these infected persons correlated with those of the previously uninfected vaccinees, indicating similar susceptibilities to spike mutation of antibodies raised by either natural infection or vaccination alone.
Vaccination of previously SARS-CoV-2-infected persons increases neutralizing potency against variants to an apparent biologic ceiling. When the prior-infected individuals were vaccinated after approximately a year (mean, 353 days after symptom onset; range, 280 to 394 days), serum neutralizing potency against the original sequence spike was relatively unchanged, but activity against all variants equalized to a level similar to the original sequence (Fig. 2A). Neutralizing potency change correlated tightly to the baseline early after infection across all individuals and variants (Fig. 2B), suggesting a consistent biologic ceiling across all variants. Again, there were no clear differences between persons receiving different vaccines. Overall, these findings indicated that the combination of natural infection and vaccination drove antibody potency to an apparent maximum for all tested variants.
FIG 2
FIG 2 Changes in SARS-CoV-2 spike variant neutralizing potency of antibodies after vaccination of persons with prior SARS-CoV-2 infection. For the 10 persons with prior COVID-19 described in the legend to Fig. 1, vaccination was initiated a mean of 353 days after symptom onset (range, 280 to 394 days), and serum neutralizing potency against each variant was determined after vaccination. (A) Potency against each variant is plotted consecutively for recent infection (18 to 45 days after the onset of symptoms; mean, 31 days) and postvaccination. Five persons received BNT162b2 (red), four persons received mRNA-1273 (blue), and one person received Ad26.COV2.S (black). The P values for comparisons between recent infection and postvaccination are given above each variant. (B) The changes in potencies against each variant are plotted against the initial potencies against each corresponding variant. Each symbol depicts the value for one variant.

Discussion.

Our results confirm that vaccine- or infection-elicited antibodies raised against the original sequence can have reduced activity against recently circulating spike variants, substantiating evidence of reduced vaccine protection against variants, such as Vaxzevria and BNT162b2 against B.1.351/Beta (46). Furthermore, our findings indicate that both mild natural infection and vaccination presenting the original spike sequence elicit antibodies with similar patterns of susceptibility to variants.
After subsequent vaccination, however, antibodies in previously infected persons gain spike neutralizing potency equal to the original sequence against all tested variants, although activity against the original sequence itself is relatively unchanged. This suggests that (i) potency against the original sequence was already maximal, and (ii) the additional antigenic exposure from vaccination further increased antibody potency against suboptimally recognized variants to reach the same maximal potency.
This gained ability is compatible with further maturation of humoral immunity after SARS-CoV-2 infection and vaccination, consistent with reports of ongoing affinity maturation after resolved infection (79). It is unclear whether our observation relates to time elapsed after infection as proposed by that report, additional maturation due to vaccination, or both. In contrast to studies showing ongoing affinity maturation, a recent report suggests that potency declines after resolution of infection (10), suggesting that vaccination has a key role in this phenomenon. Our findings also agree with two other recent reports regarding vaccination after prior COVID-19; both Wang et al. (11) and Goel et al. (12) observed that the resulting antibodies gained breadth of coverage against spike variants. Finally, we define an apparent ceiling for antiviral potency against all tested variants, which is consistent with attaining a maximal threshold of binding affinity (13, 14) for the original sequence that eventually also applies to the tested variants.
Overall, our findings raise the possibility that resistance of SARS-CoV-2 spike variants to antibodies can be overcome by driving further maturation through continued antigenic exposure by vaccination, even if the vaccine does not deliver variant sequences. Whether this can also be accomplished in SARS-CoV-2-naive persons through vaccination alone, such as delivering supplemental doses beyond the original vaccination regimen of two doses, remains to be determined.

Materials and methods. (i) Participants.

Volunteers provided informed consent under an institutional review board-approved protocol. Persons with mild SARS-CoV-2 infection were evaluated shortly after recovery from illness, and these persons as well as healthy control individuals without prior SARS-CoV-2 infection were evaluated soon after vaccination for COVID-19. The persons with prior infection all had symptom onset no later than April 2020 in the United States, when the SARS-CoV-2 variants were not yet reported to circulate, and all had mild infection that did not require hospitalization (see Table S1 in the supplemental material).

(ii) Serum ELISA for anti-RBD antibodies.

Anti-RBD antibodies were evaluated with a quantitative enzyme-linked immunosorbent assay (ELISA) as recently described in detail (10, 15). In brief, we utilized a modification of a previously reported ELISA (1618) against recombinant receptor-binding domain (RBD) protein bound to a 96-well microtiter plate, using secondary goat anti-human IgG-, IgM-, or IgA-horseradish peroxidase-conjugated detector antibodies. For quantitation, each plate contained serial dilutions of the CR3022 monoclonal antibody in IgG, IgM, or IgA formats, and the amount of binding activity in serum was expressed as an equivalent amount of the control antibody.

(iii) Serum spike-neutralizing assay and definition of neutralizing potency.

Spike neutralization activity was assessed with a spike-pseudotyped lentiviral vector assay as recently described in detail (10). Briefly, an HIV-1-based lentiviral vector delivering a luciferase reporter gene was pseudotyped with the indicated spike variant. The assay was performed by adding serial dilutions of serum during infection of angiotensin-converting enzyme 2 (ACE2)-expressing HEK 293T cells and assessing luciferase activity after 48 h. The Hill equation was utilized to estimate the dilution factor yielding 80% inhibition (DF80). The “neutralizing potency” (neutralizing activity adjusted for antibody concentration) was defined as the ratio of neutralization activity (DF80) to anti-RBD antibody concentration (log10 sum of IgG, IgM, and IgA anti-RBD antibodies in nanograms per milliliter), adjusting neutralizing activity for antibody quantity. All data are given in Table S1.

ACKNOWLEDGMENTS

We are grateful for the generous participation of the volunteers who donated their blood to these studies.
Funding was provided by AIDS Healthcare Foundation to O.Y.; private philanthropic donors (including William Moses, Mari Edelman, Beth Friedman, Dana and Matt Walden, Kathleen Poncher, Scott Z. Burns, Gwyneth Paltrow, and Brad Falchuk) to O.Y.; with additional infrastructure support from the UCLA AIDS Institute Center for AIDS Research (NIH grant AI028697), James B. Pendleton Trust, and McCarthy Foundation.
We declare that we have no commercial or other associations that pose a conflict of interest.

Supplemental Material

File (mbio.02656-21-st001.xlsx)
ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse.

REFERENCES

1.
Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, Mlisana K, von Gottberg A, Walaza S, Allam M, Ismail A, Mohale T, Glass AJ, Engelbrecht S, Van Zyl G, Preiser W, Petruccione F, Sigal A, Hardie D, Marais G, Hsiao NY, Korsman S, Davies MA, Tyers L, Mudau I, York D, Maslo C, Goedhals D, Abrahams S, Laguda-Akingba O, Alisoltani-Dehkordi A, Godzik A, Wibmer CK, Sewell BT, Lourenco J, Alcantara LCJ, Kosakovsky Pond SL, Weaver S, Martin D, Lessells RJ, Bhiman JN, Williamson C, de Oliveira T. 2021. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592:438–443.
2.
Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, Crispim MAE, Sales FCS, Hawryluk I, McCrone JT, Hulswit RJG, Franco LAM, Ramundo MS, de Jesus JG, Andrade PS, Coletti TM, Ferreira GM, Silva CAM, Manuli ER, Pereira RHM, Peixoto PS, Kraemer MUG, Gaburo N, Jr, Camilo CDC, Hoeltgebaum H, Souza WM, Rocha EC, de Souza LM, de Pinho MC, Araujo LJT, Malta FSV, de Lima AB, Silva JDP, Zauli DAG, Ferreira ACS, Schnekenberg RP, Laydon DJ, Walker PGT, Schluter HM, Dos Santos ALP, Vidal MS, Del Caro VS, Filho RMF, Dos Santos HM, Aguiar RS, Proenca-Modena JL, Nelson B, Hay JA, Monod M, Miscouridou X, et al. 2021. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372:815–821.
3.
Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD. 2021. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29:463–476.e6.
4.
Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Kwatra G, Ahmed K, Aley P, Bhikha S, Bhiman JN, Bhorat AE, Du Plessis J, Esmail A, Groenewald M, Horne E, Hwa SH, Jose A, Lambe T, Laubscher M, Malahleha M, Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A, Oelofse S, Patel F, Pillay S, Rhead S, Rodel H, Rossouw L, Taoushanis C, Tegally H, Thombrayil A, van Eck S, Wibmer CK, Durham NM, Kelly EJ, Villafana TL, Gilbert S, Pollard AJ, de Oliveira T, Moore PL, Sigal A, Ize A, et al. 2021. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 384:1885–1898.
5.
Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, Caspi I, Levy R, Leshchinsky M, Ken Dror S, Bergerzon G, Gadban H, Gadban F, Eliassian E, Shimron O, Saleh L, Ben-Zvi H, Keren Taraday E, Amichay D, Ben-Dor A, Sagas D, Strauss M, Shemer Avni Y, Huppert A, Kepten E, Balicer RD, Netzer D, Ben-Shachar S, Stern A. 2021. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med 27:1379–1384.
6.
Abu-Raddad LJ, Chemaitelly H, Butt AA. 2021. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 385:187–189. https://doi.org/10.1056/NEJMc2104974.
7.
Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Lorenzi JCC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Wang Z, Da Silva J, Poston D, Finkin S, Cho A, Cipolla M, Oliveira TY, Millard KG, Ramos V, Gazumyan A, Rutkowska M, Caskey M, Nussenzweig MC, Bjorkman PJ, Hatziioannou T, Bieniasz PD. 2021. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. bioRxiv https://doi.org/10.1101/2021.03.07.434227.
8.
Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, Cipolla M, Viant C, Barnes CO, Bram Y, Breton G, Hagglof T, Mendoza P, Hurley A, Turroja M, Gordon K, Millard KG, Ramos V, Schmidt F, Weisblum Y, Jha D, Tankelevich M, Martinez-Delgado G, Yee J, Patel R, Dizon J, Unson-O’Brien C, Shimeliovich I, Robbiani DF, Zhao Z, Gazumyan A, Schwartz RE, Hatziioannou T, Bjorkman PJ, Mehandru S, Bieniasz PD, Caskey M, Nussenzweig MC. 2021. Evolution of antibody immunity to SARS-CoV-2. Nature 591:639–644.
9.
Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, Yamada S, Kinoshita H, Nojima K, Kanno T, Tobiume M, Ishijima K, Kuroda Y, Park ES, Onodera T, Matsumura T, Takano T, Terahara K, Isogawa M, Nishiyama A, Kawana-Tachikawa A, Shinkai M, Tachikawa N, Nakamura S, Okai T, Okuma K, Matano T, Fujimoto T, Maeda K, Ohnishi M, Wakita T, Suzuki T, Takahashi Y. 2021. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. Immunity 54:1841–1852.e4. https://doi.org/10.1016/j.immuni.2021.06.015.
10.
Ibarrondo FJ, Hofman C, Fulcher JA, Goodman-Meza D, Mu W, Hausner MA, Ali A, Balamurugan A, Taus E, Elliott J, Krogstad P, Tobin NH, Ferbas KG, Kitchen SG, Aldrovandi GM, Rimoin AW, Yang OO. 2021. Primary, recall, and decay kinetics of SARS-CoV-2 vaccine antibody responses. ACS Nano 15:11180–11191.
11.
Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, Hoffmann HH, Barnes CO, Cipolla M, Ramos V, Oliveira TY, Cho A, Schmidt F, Da Silva J, Bednarski E, Aguado L, Yee J, Daga M, Turroja M, Millard KG, Jankovic M, Gazumyan A, Zhao Z, Rice CM, Bieniasz PD, Caskey M, Hatziioannou T, Nussenzweig MC. 2021. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595:426–431.
12.
Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen KA, Reynaldi A, Khoury DS, Pattekar A, Gouma S, Kuri-Cervantes L, Hicks P, Dysinger S, Hicks A, Sharma H, Herring S, Korte S, Baxter AE, Oldridge DA, Giles JR, Weirick ME, McAllister CM, Awofolaju M, Tanenbaum N, Drapeau EM, Dougherty J, Long S, D’Andrea K, Hamilton JT, McLaughlin M, Williams JC, Adamski S, Kuthuru O, UPenn COVID Processing Unit, Frank I, Betts MR, Vella LA, Grifoni A, Weiskopf D, Sette A, Hensley SE, Davenport MP, Bates P, Luning Prak ET, Greenplate AR, Wherry EJ, Adamski S, Alam Z, Addison MM, Byrne KT, et al. 2021. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science.
13.
Batista FD, Neuberger MS. 1998. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 8:751–759.
14.
Roost HP, Bachmann MF, Haag A, Kalinke U, Pliska V, Hengartner H, Zinkernagel RM. 1995. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc Natl Accad Sci USA 92:1257–1261.
15.
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, Ferbas KG, Tobin NH, Aldrovandi GM, Yang OO. 2020. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 383:1085–1087.
16.
Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V, Krammer F. 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 26:1033–1036.
17.
Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, McMahon M, Simon V, Krammer F. 2020. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr Protoc Microbiol 57:e100.
18.
Yang OO, Ibarrondo FJ. 2020. Loss of anti-SARS-CoV-2 antibodies in mild Covid-19. N Engl J Med 383:1697–1698. (Reply.).

Information & Contributors

Information

Published In

cover image mBio
mBio
Volume 12Number 621 December 2021
eLocator: e02656-21
Editors: Andrew Pekosz, Johns Hopkins University, Diane E. Griffin, Johns Hopkins Bloomberg School of Public Health

History

Received: 9 September 2021
Accepted: 1 November 2021
Published online: 7 December 2021

Keywords

  1. SARS-CoV-2
  2. COVID-19
  3. vaccines
  4. humoral immunity
  5. spike variants
  6. vaccine efficacy

Contributors

Authors

F. Javier Ibarrondo
Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
Christian Hofmann
Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
Ayub Ali
Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
Paul Ayoub
Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
Donald B. Kohn
Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
Division of Pediatric Hematology Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA

Editors

Andrew Pekosz
Invited Editor
Johns Hopkins University
Diane E. Griffin
Editor
Johns Hopkins Bloomberg School of Public Health

Notes

F. Javier Ibarrondo, Christian Hofmann, and Ayub Ali contributed equally to this work. Shared first author order was determined by timing of involvement in the project, from earlier to later.

Metrics & Citations

Metrics

Note:

  • For recently published articles, the TOTAL download count will appear as zero until a new month starts.
  • There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.
  • Citation counts come from the Crossref Cited by service.

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

View Options

Figures and Media

Figures

Media

Tables

Share

Share

Share the article link

Share with email

Email a colleague

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy